UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000563
Receipt number R000000679
Scientific Title Study of letrozole in postmenopausal patients with breast cancer (JBCRG M02)
Date of disclosure of the study information 2006/12/27
Last modified on 2021/08/06 11:10:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of letrozole in postmenopausal patients with breast cancer (JBCRG M02)

Acronym

JBCRG-M02
(Study of letrozole in postmenopausal patients with breast cancer)

Scientific Title

Study of letrozole in postmenopausal patients with breast cancer (JBCRG M02)

Scientific Title:Acronym

JBCRG-M02
(Study of letrozole in postmenopausal patients with breast cancer)

Region

Japan


Condition

Condition

Postmenopausal patients with breast cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of letrozole in postmenopausal patients with metastatic or locally advanced breast cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Clinical responce rate by hormone receptor status (Allred score) and Her2 status

Key secondary outcomes

Time to progression, advertse events, expression of hormone receptor-related factors


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Letrozole 2.5 mg/day

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Postmenopausal women
Metastatic or locally advanced breast cancer
Hormone receptor positive breast cancer
Measureable lesion
Adequate organ function
PS 0-2
Written informed concent

Key exclusion criteria

Inflammatory breast cancer
Lymphangitic lung metastasis
Brain metastasis
Diffuse liver metastasis
Active double cancer
Prior aromatase inhibitors within one year

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Katsumasa
Middle name
Last name Kuroi

Organization

Metropolitan Komagome Hospital

Division name

Surgery Dept

Zip code

113-8677

Address

3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677 Japan

TEL

03-3823-2101

Email

kurochan@dd.iij4u.or.jp


Public contact

Name of contact person

1st name Jun
Middle name
Last name Fukase

Organization

Japan Breast Cancer Research Group (JBCRG)

Division name

Head office

Zip code

103-0016

Address

9-4-3F, Nihonbashikoamicho, Chuo-ku, Tokyo 103-0016, Japan

TEL

03-6264-8873

Homepage URL

https://www.jbcrg.jp/

Email

office@jbcrg.jp


Sponsor or person

Institute

Japan Breast Cancer Research Group (JBCRG)

Institute

Department

Personal name



Funding Source

Organization

Japan Breast Cancer Research Group (JBCRG)

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Japan Breast Cancer Research Group (JBCRG)

Address

9-4-3F, Nihonbashikoamicho, Chuo-ku, Tokyo 103-0016, Japan

Tel

03-6264-8873

Email

office@jbcrg.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

市立堺病院(大阪府)、広島市立安佐市民病院(広島県)、八尾市立病院(大阪府)、四国がんセンター(愛媛県)、名古屋市立東市民病院(愛知県)、大阪医療センター(大阪府)、都立駒込病院(東京都)


Other administrative information

Date of disclosure of the study information

2006 Year 12 Month 27 Day


Related information

URL releasing protocol

https://upload.umin.ac.jp/cgi-bin/ctr/ctr_up_reg_f5.cgi

Publication of results

Published


Result

URL related to results and publications

NA

Number of participants that the trial has enrolled

50

Results

CR2, PR16, SD over 24 weeks 20, PD1

Results date posted

2021 Year 08 Month 06 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Average age 64.6; locally advanced 3, recurrent 30, metastatic 14, unknown 3 ; Soft tissue only 16, visceral 26, bone only 5, unknown 3

Participant flow

Treatment, clinical evaluation n=50

Adverse events

Grade 3,4 2(4%)

Outcome measures

Clinical response, adverse effect

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2006 Year 09 Month 25 Day

Date of IRB

2006 Year 12 Month 20 Day

Anticipated trial start date

2007 Year 02 Month 20 Day

Last follow-up date

2013 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2006 Year 12 Month 27 Day

Last modified on

2021 Year 08 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000679


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name